无佐剂支气管败血波氏杆菌提取物疫苗联合重组百日咳杆菌素皮下接种犬的功效与安全性
本研究通过攻击试验和现场试验评估无佐剂支气管败血波氏杆菌提取物疫苗(含重组百日咳杆菌素)在犬中的功效与安全性。攻击试验中,40只8周龄比格犬随机接种疫苗或安慰剂,疫苗组连续咳嗽两天的比例显著低于对照组,咳嗽持续时间更短,排菌减少且抗体滴度更高。现场试验中,624只犬接种1242剂次,不良反应罕见(0.56%)、轻微且短暂,无严重反应。
要点
- 疫苗组连续咳嗽两天的比例为5.0%,显著低于对照组的80.0%。
- 疫苗组咳嗽持续时间(3.2天)显著短于对照组(16.0天)。
- 现场试验中不良反应发生率为0.56%,均为轻微短暂反应。
核心结论
- 该无佐剂疫苗可显著减少犬的咳嗽和细菌排菌,并诱导强免疫应答。
- 疫苗在多样犬群中耐受良好,支持其作为安全有效的预防措施。
研究设计与样本
- 攻击试验:40只8周龄比格犬随机分为两组,分别在第0天和第21天皮下接种两剂安慰剂或疫苗,第42天以雾化强毒支气管败血波氏杆菌攻击。
- 现场试验:624只客户 owned 犬,间隔3-4周皮下接种两剂,评估安全性。
主要发现
- 攻击后,疫苗组仅1/20(5.0%)出现连续两天咳嗽,对照组为16/20(80.0%)(P = 0.0014)。
- 疫苗组咳嗽持续时间(3.2天)显著短于对照组(16.0天)。
- 疫苗组排菌减少,攻击后抗体滴度显著更高(p < 0.0001)。
- 现场试验中,1242剂次接种后不良反应发生率为0.56%,轻微且短暂,无严重反应。
临床怎么用
- 该疫苗可作为预防犬支气管败血波氏杆菌感染的皮下接种选择。
- 接种方案为间隔3-4周皮下接种两剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to assess the efficacy and safety of the Vanguard® Recombishield™ Injectable Bordetella, a non-adjuvanted Bb extract vaccine containing recombinant pertactin, in dogs using controlled challenge and field studies. METHODS: In the challenge study, 40 eight-week-old beagle puppies were randomly assigned to two groups to receive two subcutaneous doses of either placebo or vaccine on Days 0 and 21. On Day 42, all dogs were challenged with aerosolized virulent Bb. Clinical signs were monitored regularly, with two consecutive days of coughing as the primary efficacy variable. Nasal swabs for bacterial isolation were collected on Days -10, 0, every other day from Day 42 to 70. Antibody titers were measured on Days -10, 0, 21, 42 and 70. A separate field study assessed vaccine safety in 624 client-owned dogs, each of which received two subcutaneous doses 3-4 weeks apart. Veterinarians monitored immediate post-vaccination reactions for 10-20 min, while owners reported delayed adverse health events from the first dose through 10 days after the second dose. RESULTS: Vaccinated puppies exhibited substantially reduced clinical signs following challenge. Only 1 out of 20 (5.0%) vaccinated puppies experienced coughing over two consecutive days, compared to 16 out of 20 (80.0%) in the control group (P = 0.0014). The duration of coughing was significantly shorter in vaccinated puppies (3.2 days) than in controls (16.0 days). Additionally, vaccinated puppies exhibited reduced bacterial shedding and developed significantly higher post-challenge antibody titers (p < 0.0001). In the field study, adverse events were rare (0.56%), mild, and transient, with no serious reactions reported among the 1242 administered doses. CONCLUSIONS: Vanguard® Recombishield™ Injectable Bordetella significantly reduced coughing and bacterial shedding, while eliciting a strong immune response. Vaccine was well tolerated in a diverse canine population, supporting its use as a safe and effective preventive measure against Bb infection.
引用
- Velineni S, Wappel S, Sobell N, et al. Efficacy and safety of a non-adjuvanted Bordetella bronchiseptica extract vaccine with recombinant pertactin administered subcutaneously to dogs. Vaccine. 2026. PMID: 42468227. doi:10.1016/j.vaccine.2026.128941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。